In the global competition for biopharmaceutical investment policy environments either enable or hinder an economy’s capacity to compete. Today who is winning this race and who is trailing? What aspects of individual economies’ environments are providing momentum and what is holding them back? And ultimately, how can governments improve their competitiveness and secure a larger piece of global biomedical investment?
To answer these questions we turned to biopharmaceutical country executives, who are at the forefront of understanding how different aspects of ...Continue Reading →